Abstract
Background: Atherosclerosis (AS) is a chronic inflammatory disease that contributes to multiple cardiovascular diseases (CVDs), and foam cell formation plays important roles in the progression of AS. There is an urgent need to identify new molecular targets for treating AS, and thereby improve the quality of life and reduce the financial burden of individuals with CVD.Methods: An in vitro model of AS was generated by treating THP-1 cells and human aortic vascular smooth muscle cells (HA-VSMCs) with oxidized low-density lipoproteins (ox-LDLs). HA-VSMC proliferation and foam cell formation were detected by the MTT assay and Oil Red O staining. C–X–C motif chemokine 12 (CXCL12) expression was suppressed by siRNA. An AS rat model was established by feeding rats a high-fat diet and vitamin D2 for 3 weeks. Histopathology examinations were conducted by Hematoxylin and Eosin (H&E) staining and the levels ionized calcium-binding adapter molecule 1 (IBA1) and α smooth muscle actin (α-SMA) expression were determined by ELISA assays and immunohistochemistry.Results: An in vitro model of AS was established with THP-1 cells. CXCL12 expression in the model THP-1 cells was significantly increased when compared with its expression in control cells. Suppression of CXCL12 expression reduced the progression of AS in the cell model. Moreover, CXCL12 promoted AS in the in vivo rat model.Conclusion: Our results suggest that CXCL12 plays an important role in promoting the progression of AS. Furthermore, inhibition of CXCL12 might suppress the development of AS by inhibiting HA-VSMC proliferation and their transformation to foam cells.
Highlights
Atherosclerosis (AS) is a multi-step process that causes cardiovascular diseases (CVDs) by obstructing blood flow to the heart, brain or lower extremities via luminal stenosis or thrombosis [6]
Our results showed that C–X–C motif chemokine 12 (CXCL12) expression was significantly increased in oxidized low-density lipoprotein (ox-low-density lipoproteins (LDLs))-treated cells (Figure 1B), suggesting that CXCL12 was induced in the AS cell model
Our results showed that co-culture with ox-LDL-treated THP-1 cells significantly increased the proliferation of human aortic vascular smooth muscle cell (HA-vascular smooth muscle cell (VSMC)) when compared with the proliferation non-co-cultured HA-VSMCs (Figure 3A)
Summary
Atherosclerosis (AS) is a multi-step process that causes cardiovascular diseases (CVDs) by obstructing blood flow to the heart, brain or lower extremities via luminal stenosis or thrombosis [6]. Dysfunction of endothelial cells is the initial event in AS, and is followed by the release of low-density lipoproteins (LDLs), invasion of macrophages and vascular smooth muscle cells (VSMCs), foam cell formation, and extracellular matrix remodeling, all of which complete the AS process [31]. Atherosclerosis (AS) is a chronic inflammatory disease that contributes to multiple cardiovascular diseases (CVDs), and foam cell formation plays important roles in the progression of AS. Methods: An in vitro model of AS was generated by treating THP-1 cells and human aortic vascular smooth muscle cells (HA-VSMCs) with oxidized low-density lipoproteins (ox-LDLs). Suppression of CXCL12 expression reduced the progression of AS in the cell model. Inhibition of CXCL12 might suppress the development of AS by inhibiting HA-VSMC proliferation and their transformation to foam cells
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
